Journal of Multiple Sclerosis

Department of Neurology, National Institute of Neurosciences & Hospital (NINS), Bangladesh

Publications

• Short Commentary   
  Ups and Downs in MS Therapeutics
  Author(s): Abdul Aftab and Pankaj Majlumdar*
  
  Over the past three decades, there has been a remarkable surge in the approval of drugs for treating Multiple Sclerosis (MS), with the number now exceeding 15 options, including various dosages and generics. However, while these treatments have primarily targeted the inflammatory activity underlying relapses, the progressive aspects of MS, characterized by a gradual worsening of disability without relapses, remain inadequately addressed. Siponimod and Ocrelizumab have emerged as crucial drugs approved for treating progressive forms of MS, particularly primary progressive and secondary progressive MS. Despite their benefits for patients experiencing clinical relapses or displaying disease activity in MRI scans, their use is limited to those with active disease as per regulators in the US and Europe. This leaves a significant treatment gap for patients with progressive MS lacking active.. View More»
  DOI: 10.35248/2376-0389.24.11.1.535

  Abstract HTML PDF